Max Healthcare Institute Full Year 2025 Earnings: Misses Expectations

Max Healthcare Institute (NSE:MAXHEALTH) Full Year 2025 Results

Key Financial Results

• Revenue: ₹70.3b (up 30% from FY 2024).
• Net income: ₹10.8b (up 1.7% from FY 2024).
• Profit margin: 15% (down from 20% in FY 2024). The decrease in margin was driven by higher expenses.
• EPS: ₹11.07 (up from ₹10.89 in FY 2024).

This technology could replace computers: discover the 20 stocks are working to make quantum computing a reality.

All figures shown in the chart above are for the trailing 12 month (TTM) period

Max Healthcare Institute Revenues and Earnings Miss Expectations

Revenue missed analyst estimates by 17%. Earnings per share (EPS) also missed analyst estimates by 24%.

In the last 12 months, the only revenue segment was Medical and Healthcare Services contributing ₹70.3b. The largest operating expense was General & Administrative costs, amounting to ₹14.7b (45% of total expenses). Explore how MAXHEALTH's revenue and expenses shape its earnings.

Looking ahead, revenue is forecast to grow 24% p.a. on average during the next 3 years, compared to a 17% growth forecast for the Healthcare industry in India.

Performance of the Indian Healthcare industry.

The company's shares are down 2.9% from a week ago.

Balance Sheet Analysis

While earnings are important, another area to consider is the balance sheet. We have a graphic representation of Max Healthcare Institute's balance sheet and an in-depth analysis of the company's financial position.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.